The regulatory environment for tirzepatide has changed substantially since the FDA confirmed that the tirzepatide injection drug shortage has been resolved. MEDVi, a telehealth platform based in Newark, Delaware, has emerged as a significant player in providing access to GLP-1 weight loss medications, including tirzepatide.
Founded by Matthew Gallagher, MEDVi has seen remarkable growth, achieving $401 million in sales in 2025 and projecting to reach $1.8 billion in 2026. Gallagher noted, “Growth was insane,” highlighting the rapid expansion of the company from just 300 customers in its first month to 1,300 in the second month.
MEDVi offers a variety of pricing options for its compounded GLP-1 medications. The first month cost for compounded GLP-1 injections starts at $179, with monthly refills priced at $299. For those preferring an oral option, compounded GLP-1 tablets are available starting at $249 per month. In contrast, the branded Ozempic injection is listed at a staggering $1,999 per month.
In addition to its competitive pricing, MEDVi has implemented a conditional refund policy for weight loss after five months, which requires a minimum commitment before a refund can be requested. This policy reflects MEDVi’s confidence in the effectiveness of its offerings, although it emphasizes that “the evaluating clinician retains the decision to prescribe.”
As the market for weight loss medications continues to evolve, MEDVi’s innovative approach, utilizing over a dozen AI tools and strategic partnerships, positions it well within the healthcare landscape. The company achieved a net profit margin of 16.2% in 2025, generating approximately $65 million in profit.
Observers note that MEDVi’s success could have broader implications for the telehealth industry, particularly in how patients access essential medications. The body takes time to acclimate to GLP-1 medication, and MEDVi’s model aims to support patients throughout this process.
As MEDVi continues to grow and adapt to the changing healthcare environment, stakeholders are keenly watching how it will navigate the complexities of the pharmaceutical market and maintain its competitive edge.
